NYSE - Nasdaq Real Time Price USD
Arcus Biosciences, Inc. (RCUS)
8.67
-0.13
(-1.48%)
At close: May 13 at 4:00:02 PM EDT
8.70
+0.03
+(0.35%)
After hours: May 13 at 7:49:08 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 4 |
| Avg. Estimate | -1.17 | -1.18 | -4.76 | -4.88 |
| Low Estimate | -1.21 | -1.24 | -5.04 | -5.54 |
| High Estimate | -1.1 | -1.13 | -4.52 | -3.93 |
| Year Ago EPS | -1.02 | -1 | -2.92 | -4.76 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 10 | 10 |
| Avg. Estimate | 32.86M | 32.48M | 127.51M | 168.66M |
| Low Estimate | 20M | 20M | 87.7M | 44M |
| High Estimate | 65M | 65M | 200M | 283.67M |
| Year Ago Sales | 39M | 48M | 258M | 127.51M |
| Sales Growth (year/est) | -15.75% | -32.33% | -50.58% | 32.27% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -1.39 | -1.07 | -1.2 | -1.08 |
| EPS Actual | -1.02 | -1 | -1.03 | -1.14 |
| Difference | 0.37 | 0.07 | 0.17 | -0.06 |
| Surprise % | 26.38% | 6.32% | 14.39% | -5.26% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.17 | -1.18 | -4.76 | -4.88 |
| 7 Days Ago | -1 | -1.02 | -4.01 | -4.23 |
| 30 Days Ago | -1 | -1.02 | -4.01 | -4.25 |
| 60 Days Ago | -1.09 | -1.14 | -4.13 | -4.2 |
| 90 Days Ago | -1.12 | -1.17 | -3.66 | -4.03 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | 2 | 2 | 2 | 2 |
| Down Last 30 Days | -- | 2 | 2 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RCUS | -14.25% | -18.23% | -63.13% | -2.41% |
| S&P 500 | 13.17% | 3.05% | 8.05% | 13.75% |
Upgrades & Downgrades
| Maintains | Morgan Stanley: Overweight to Overweight | 5/9/2025 |
| Maintains | Goldman Sachs: Neutral to Neutral | 5/8/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 5/7/2025 |
| Maintains | Barclays: Overweight to Overweight | 4/23/2025 |
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 2/26/2025 |
| Maintains | B of A Securities: Neutral to Neutral | 2/19/2025 |
Related Tickers
KURA Kura Oncology, Inc.
5.80
-4.76%
ORIC ORIC Pharmaceuticals, Inc.
5.31
-1.85%
SNDX Syndax Pharmaceuticals, Inc.
10.19
-7.28%
IDYA IDEAYA Biosciences, Inc.
17.45
-4.90%
BCYC Bicycle Therapeutics plc
8.11
-5.70%
NRIX Nurix Therapeutics, Inc.
9.73
-4.42%
VERA Vera Therapeutics, Inc.
21.58
-4.05%
XNCR Xencor, Inc.
8.11
-7.53%
RYTM Rhythm Pharmaceuticals, Inc.
56.79
-3.69%
AKRO Akero Therapeutics, Inc.
40.01
-3.66%